Joachim P. Steinbach

Author

Also Known As

Dietmar Krex, J P Steinbach, J Steinbach, J. P. Steinbach, J. Steinbach, J.P. Steinbach, JOACHIM P. STEINBACH, Joachim P Steinbach, Joachim P. Steinbach, Joachim Peter Steinbach

329

Publications

13.3K

Citations

H-Index

133

Concepts

All Affiliations

Goethe University Frankfurt University Hospital Frankfurt Heidelberg University German Cancer Research Center Frankfurt Cancer Institute

About

Joachim P. Steinbach is an author at Goethe University Frankfurt specializing in medicine, glioma, and neuro-oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	57	6.3K
2	Health Sciences	14	18	1.3K
3	Engineering	4	4	249
4	Social Sciences	4	4	513
5	Biochemistry	2	2	89

Joachim P. Steinbach

119

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Wolfgang Wick, Michael Platten, Christoph Meisner, The Lancet Oncology Neuro-oncologyTemozolomide ChemotherapyMalignant AstrocytomaRadiation TherapyMedicine	2012	1.1K
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Roger Stupp, Monika E. Hegi, Thierry Gorlia, The Lancet Oncology Neuro-oncologyGliomaMedicineStandard TreatmentPathology	2014	1K
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network Michael Weller, Jörg Felsberg, Christian Hartmann, Journal of Clinical Oncology	2009	606
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, The Lancet Hematological MalignancyNeuro-oncologyTreatment StrategiesMedicineStandard Temozolomide Therapy	2019	556
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter Michael Lim, Michael Weller, Ahmed Idbaïh, Neuro-Oncology	2022	450
A vaccine targeting mutant IDH1 in newly diagnosed glioma Michael Platten, Lukas Bunse, Antje Wick, Nature	2021	400
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis Norbert Sommer, P.-A. Löschmann, G.H. Northoff, Nature Medicine InflammationPsychoneuroimmunologyAutoimmune DiseasePsychiatryMedicine	1995	343
<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Clinical Cancer Research	2015	311
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups Michael Weller, Ruthild G. Weber, Edith Willscher, Acta Neuropathologica PathologyHigh-grade GliomasBrain LesionGliomaTranscriptome-wide Profiling	2015	307
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma Johannes Rieger, Oliver Bähr, Gabriele D. Maurer, International Journal of Oncology NutritionRecurrent GliomaKetogenic DietChemoprevention StrategyPathology	2014	270

Page 1